SPX3,585.62-54.85 -1.51%
DIA287.30-4.91 -1.68%
IXIC10,575.62-161.89 -1.51%

eFFECTRO Therapeutics Says First Patient Dosed in Second Cohort of Phase 1B Clinical Trial of Zotatifin for COVID-19

eFFECTRO Therapeutics Says First Patient Dosed in Second Cohort of Phase 1B Clinical Trial of Zotatifin for COVID-19

MT Newswires · 09/14/2022 06:23

Please log in to view news